Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.03 AUD | -3.23% | -9.09% | -26.83% |
Feb. 22 | PharmX Technologies Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 6.404 | 7.685 | 17.31 | 51.92 | 20.29 | 22.1 |
Enterprise Value (EV) 1 | 1.433 | 5.352 | 15.72 | 45.76 | 14.86 | 9.329 |
P/E ratio | 25.5 x | -1.83 x | 84.5 x | 43.5 x | 85.2 x | -20.8 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 0.51 x | 0.68 x | 1.63 x | 3.88 x | 1.7 x | 3.61 x |
EV / Revenue | 0.11 x | 0.48 x | 1.48 x | 3.42 x | 1.24 x | 1.52 x |
EV / EBITDA | 1.53 x | 6.25 x | 16.8 x | 27.2 x | 16.1 x | -42.6 x |
EV / FCF | -0.29 x | -1.43 x | -5.33 x | 15 x | -8.47 x | -11 x |
FCF Yield | -346% | -69.8% | -18.8% | 6.68% | -11.8% | -9.09% |
Price to Book | 0.45 x | 0.77 x | 1.31 x | 2.26 x | 0.87 x | 1 x |
Nbr of stocks (in thousands) | 256,168 | 256,168 | 402,568 | 596,757 | 596,757 | 597,382 |
Reference price 2 | 0.0250 | 0.0300 | 0.0430 | 0.0870 | 0.0340 | 0.0370 |
Announcement Date | 9/26/18 | 8/29/19 | 8/23/20 | 8/17/21 | 8/29/22 | 8/22/23 |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 12.57 | 11.23 | 10.64 | 13.38 | 11.95 | 6.127 |
EBITDA 1 | 0.939 | 0.856 | 0.937 | 1.682 | 0.921 | -0.219 |
EBIT 1 | 0.65 | 0.561 | 0.685 | 1.236 | 0.369 | -0.665 |
Operating Margin | 5.17% | 5% | 6.44% | 9.24% | 3.09% | -10.85% |
Earnings before Tax (EBT) 1 | 0.65 | -3.983 | 0.458 | 1.359 | 0.298 | -0.719 |
Net income 1 | 0.251 | -4.205 | 0.176 | 1.091 | 0.252 | -1.051 |
Net margin | 2% | -37.44% | 1.65% | 8.15% | 2.11% | -17.15% |
EPS 2 | 0.000979 | -0.0164 | 0.000509 | 0.001999 | 0.000399 | -0.001781 |
Free Cash Flow 1 | -4.954 | -3.736 | -2.952 | 3.056 | -1.754 | -0.8484 |
FCF margin | -39.42% | -33.27% | -27.74% | 22.83% | -14.67% | -13.85% |
FCF Conversion (EBITDA) | - | - | - | 181.66% | - | - |
FCF Conversion (Net income) | - | - | - | 280.06% | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 9/26/18 | 8/29/19 | 8/23/20 | 8/17/21 | 8/29/22 | 8/22/23 |
Income Statement Evolution (Quarterly data)
Fiscal Period: June | 2023 S2 |
---|---|
Net sales 1 | 5.902 |
EBITDA 1 | -0.517 |
EBIT 1 | -0.29 |
Operating Margin | -4.91% |
Earnings before Tax (EBT) | - |
Net income | - |
Net margin | - |
EPS | - |
Dividend per Share | - |
Announcement Date | 8/22/23 |
Balance Sheet Analysis
Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 4.97 | 2.33 | 1.59 | 6.16 | 5.43 | 12.8 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -4.95 | -3.74 | -2.95 | 3.06 | -1.75 | -0.85 |
ROE (net income / shareholders' equity) | 1.78% | -34.7% | 1.55% | 6.04% | 0.08% | -3.89% |
ROA (Net income/ Total Assets) | 2.06% | 2.02% | 2.5% | 3.06% | 0.74% | -1.24% |
Assets 1 | 12.2 | -208.5 | 7.033 | 35.68 | 33.94 | 85.08 |
Book Value Per Share 2 | 0.0600 | 0.0400 | 0.0300 | 0.0400 | 0.0400 | 0.0400 |
Cash Flow per Share 2 | 0.0200 | 0.0100 | 0.0100 | 0.0100 | 0.0100 | 0.0200 |
Capex 1 | 0.28 | 0.27 | 0.16 | 0.3 | 0.1 | 0.09 |
Capex / Sales | 2.2% | 2.4% | 1.47% | 2.24% | 0.8% | 1.39% |
Announcement Date | 9/26/18 | 8/29/19 | 8/23/20 | 8/17/21 | 8/29/22 | 8/22/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+19.07% | 414B | |
+15.27% | 242B | |
+20.63% | 104B | |
+17.19% | 83.87B | |
+54.11% | 57.64B | |
+33.59% | 53.37B | |
+6.02% | 37.83B | |
+15.88% | 34.11B | |
-8.32% | 23.18B |
- Stock Market
- Equities
- PHX Stock
- PHX Stock
- Financials PharmX Technologies Limited